Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001615774-17-006255
Filing Date
2017-11-06
Accepted
2017-11-06 16:32:11
Documents
54
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q s107901_10q.htm 10-Q 403349
2 EXHIBIT 31.01 s107901_ex31-1.htm EX-31.01 15146
3 EXHIBIT 31.02 s107901_ex31-2.htm EX-31.02 10226
4 EXHIBIT 32.01 s107901_ex32-1.htm EX-32.01 8338
  Complete submission text file 0001615774-17-006255.txt   3003516

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE tnxp-20170930.xml EX-101.INS 511165
6 XBRL SCHEMA FILE tnxp-20170930.xsd EX-101.SCH 36927
7 XBRL CALCULATION FILE tnxp-20170930_cal.xml EX-101.CAL 38317
8 XBRL DEFINITION FILE tnxp-20170930_def.xml EX-101.DEF 137031
9 XBRL LABEL FILE tnxp-20170930_lab.xml EX-101.LAB 298902
10 XBRL PRESENTATION FILE tnxp-20170930_pre.xml EX-101.PRE 220516
Mailing Address 509 MADISON AVE. - SUITE 306 NEW YORK NY 10022
Business Address 509 MADISON AVE. - SUITE 306 NEW YORK NY 10022 1-800-849-7894
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36019 | Film No.: 171179803
SIC: 2834 Pharmaceutical Preparations